» Download Public Reports
About 200 reports
- Company report
- February 2013
- 5 pages
January 2013
... In as it appears to be trending slower over time. Patents on medicines in australia have a five year data protection for clinical trial data submitted for regulatory approval, while most other industrialised ...
January 2013
... Protection there would be no return on investment, and no re-investment in research, which leads to the discovery of new and innovative medicines such as new cures and treatments for cancers. Research ...
March 2013
... Of professional programs and services that aim to improve consumer health outcomes. These include services to support medication management, programs to assist the pharmacy workforce, activities to support ...
March 2013
... Placement of $170m to new and existing institutional investors 14-mar-13 qrx qrx pharma fda sets 26 august as new pdufa date for the resubmitted new drug application for moxduo-ir 15-mar-13 bne bone medical ...
March 2013
... Commercial rollout of vitrogro in europe. Top international stories amgen reports positive phase-3 data for melanoma vaccine:- which it acquired as part of biovex that it bought two years ago for up to $1 ...
January 2013
... First produced a vaccine To combat 1918 Spanish flu Pandemic, though at this time influenza was regarded as a bacterial disease Been producing flu vaccine in eggs since mid-1940s Current ...
March 2013
... For multiple suppliers Low marginal cost of production The (relevant) policy issue is what should the subsidised price be 6 Grattan analyses Identified the 50 drug-dose combinations that are highest ...
» Purchase Premium Reports
(From $ 125 - $ 3 500)
77 reports
- $ 3 500
- Industry report
- April 2013
- by GBI Research
Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants ...
February 2013
$ 2 000
This report provides data on the therapeutic development for Nausea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in ...
March 2013
$ 2 000
This report provides data on the therapeutic development for Tetanus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in ...
April 2013
$ 2 000
This report provides data on the therapeutic development for Diphtheria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...
May 2013
$ 1 088
Includes 3 FREE quarterly updates BMI View: Given the country's increasingly ageing population and the consequential rise in noncommunicable diseases, Australia is a highly attractive place for multinational ...
May 2013
$ 652
This market research report offers a perspective on the actual market situation, trends and future outlook for vaccines in Australia. The study provides essential market information for decision-makers ...
March 2013
$ 250
This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...